Jean George

Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Cyteir Therapeutics, Disarm Therapeutics (acquired by Eli Lilly), Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Locanabio Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics (acquired by Gilead), Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).

Jean George is the General Partner at Lightstone Ventures, based in United States, North America. With a background in Financial Services, Jean George has a rich history of leadership and innovation. Jean George studied BS Biology @ University of Maine. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.